The UK has the potential to become the global leader in pharmaceutical cannabinoid R&D, according to a new report published by the Cannabinoid Research and Development Group (CRDG). The report suggests the UK can build on the success of GW Pharmaceuticals, whose multiple sclerosis treatment product nabiximols was the first natural cannabis plant derivative to […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!